• Cynata raises $1.2m through At-The-Market Subscription Agreement with Acuity Capital
• Funds will be used for working capital
• Shares issued at $0.28, representing an 11.1% discount to last traded price

Cynata Therapeutics Limited (ASX: 'CYP' or 'Cynata'), a clinical-stage biotechnology company specialising in cell therapeutics, has announced that it has utilised its At-the-Market Subscription Agreement ('ATM') with Acuity Capital to raise $1,204,000 (net of costs). The funds were raised through the set-off of 4,300,000 fully paid ordinary Cynata shares previously issued to Acuity Capital under the ATM ('Set-off Shares'). The Set-off Shares have a deemed issue price of $0.28 per share, which represents a discount of 11.1% to the last traded price of $0.315 on 23 January 2026. The funds raised will be put towards working capital. Cynata Therapeutics is a clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on its proprietary Cymerus™ therapeutic stem cell platform technology. The company has demonstrated positive safety and efficacy data for its Cymerus™ product candidates in Phase 1 clinical trials and has further clinical trials ongoing, including a Phase 2 trial of CYP-001 in graft versus host disease (GvHD), a Phase 1/2 trial of CYP-001 in patients undergoing kidney transplantation, and a Phase 3 trial of CYP-004 in osteoarthritis.